Evidence map›Paper›PMID 40242441›Full record

ArticleFrontiers in pharmacology2025

Therapeutic potential and mechanistic insights of silibinin targeting cancer-associated fibroblasts in colorectal cancer.

Shenglan He, Jianmei Ji, Kaisi Zhu, Youlan Chen, Xiaowen Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shenglan He *Department of Gastroenterology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jianmei Ji *Department of Digestive Endoscopy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Kaisi ZhuDepartment of Anesthesiology, Changhai Hospital, Navy Medical University, Shanghai, China.
Youlan ChenInstitute of Integrated Traditional Chinese and Western Medicine Digestive Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xiaowen XuDepartment of Digestive Endoscopy, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aims to elucidate the role of SB in inhibiting CRC progression by targeting CAFs and elucidating the underlying mechanisms. Methods: In this study, a spontaneous CRC model induced by AOM/DSS was used to evaluate the effects of SB on CAFs. Mice were treated with SB, and tumor burden was assessed by colon length. CAFs were isolated post-treatment for transcriptomic analysis to identify differentially expressed genes, with molecular docking providing Results: Conclusion: These results demonstrated that SB holds promise as a therapeutic agent for targeting CAFs in CRC. This study advances our understanding of SB's mechanisms, particularly its inhibitory effects on CAFs proliferation, colony formation, and migration.

Indexed as

antimigrationanti-proliferationcancer-associated fibroblastscolorectal cancersilibinin

Identifiers

PMID40242441
PMCPMC12000085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.